Skip to main content
Equibles
PACB logo

PACB · Pacific Biosciences Of California, Inc. · Earnings Call Transcripts & Audio

Track PACB — free

Use PACB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PACB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.41 +0.04 (+1.69%)
Russell 2000 member Rebalance outlook locked
Market Cap
$503.55M
Shares
310.83M
Volume · Oct 1 7.83M Avg daily vol (3M) 8.02M

Pacific Biosciences Of California, Inc. Earnings Call Transcripts

Quarterly earnings calls for Pacific Biosciences Of California, Inc. (PACB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼7.4% $32.31M −$76.97M '22 Q3 22-10-26 ▼24.1% $27.35M −$84.38M '22 Q4 23-01-09 ▲17.3% $38.90M −$88.02M '23 Q1 23-05-02 ▲34.1% $47.57M −$69.83M '23 Q2 23-08-02 ▲72.4% $55.69M −$66.87M '23 Q3 23-10-30 ▲113.3% $58.36M −$82.02M '23 Q4 24-02-15 ▼0.2% $38.81M −$78.18M '24 Q1 24-05-09 ▼24.3% $36.01M −$173.32M '24 Q2 24-08-07 ▼28.2% $39.97M −$60.73M '24 Q3 24-11-07 ▼32.8% $39.22M $2.37M '24 Q4 25-02-13 ▼4.3% $37.15M −$426.07M '25 Q1 25-04-09 ▲10.4% $39.77M −$41.93M '25 Q2 25-08-07 ▼3.8% $38.44M −$38.00M '25 Q3 25-11-05 ▲13.8% $44.65M −$40.37M '25 Q4 26-02-12 ▲0.1% $37.18M −$8.28M '26 Q1 26-05-07 LATEST ▼1.9% $39.01M −$44.74M '26 Q2 26-08-05
Annual General Meeting
Investor event
2026-12-01
Pacific Biosciences Of California, Inc. (PACB) December 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-11-18
Pacific Biosciences Of California, Inc. (PACB) November 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-11-17
Pacific Biosciences Of California, Inc. (PACB) November 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-09-24
Pacific Biosciences Of California, Inc. (PACB) September 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Pacific Biosciences Of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Balanced tone HiFi platform and consumables Sparknext chemistry launch Clinical market growth
Revenue
$39.01M
▼ 1.9% YoY
Diluted EPS
$-0.14
Gross margin
32.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Pacific Biosciences Of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Positive tone Consumables / Clinical Growth Vega Instruments Revio Installed Base
Revenue
$37.18M
▲ 0.1% YoY
Diluted EPS
$-0.03
Gross margin
34.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Pacific Biosciences Of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
Positive tone Instrument Placements (Revio and Vega) Consumables Growth and Clinical Adoption Gross Margin Expansion
Revenue
$44.65M*
▲ 13.8% YoY
Gross margin
37.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Pacific Biosciences Of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
Positive tone Revio System Clinical and HiFi Adoption Revenue and Guidance
Revenue
$38.44M
▼ 3.8% YoY
Diluted EPS
$-0.13
Gross margin
41.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Pacific Biosciences Of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
Positive tone Revenue and growth Revio placements and utilization Vega platform adoption
Revenue
$39.77M
▲ 10.4% YoY
Diluted EPS
$-0.14
Gross margin
36.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-09
Pacific Biosciences Of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
Cautious tone Product platforms: Revio, Vega, Spark, multi-use SMRT Cells Clinical and regional growth opportunities (EMEA, hospitals) Consumables growth and pull-through
Revenue
$37.15M
▼ 4.3% YoY
Diluted EPS
$-1.44
Gross margin
-3.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Pacific Biosciences Of California, Inc. (PACB) Q4 2024 Earnings Call Transcript
Balanced tone Macroeconomic and NIH Funding Uncertainty Revio and Consumables Vega Benchtop Platform
Revenue
$39.22M*
▼ 32.8% YoY
Gross margin
25.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Pacific Biosciences Of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
Positive tone Product Launches (SPRQ/SpaRC, Vega) Revio Platform Adoption SoftBank Note Exchange / Balance Sheet
Revenue
$39.97M
▼ 28.2% YoY
Diluted EPS
$-0.22
Gross margin
25.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Pacific Biosciences Of California, Inc. (PACB) Q2 2024 Earnings Call Transcript
Cautious tone Revio Instrument Demand Challenges Consumables and Revio Utilization Restructuring and Cost Reduction
Revenue
$36.01M
▼ 24.3% YoY
Diluted EPS
$-0.64
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Pacific Biosciences Of California, Inc. (PACB) Q1 2024 Earnings Call Transcript
Cautious tone Revio instrument sales cycle elongation Cost reduction and margin improvement Long-term cash flow positive goal by 2026
Revenue
$38.81M
▼ 0.2% YoY
Diluted EPS
$-0.29
Gross margin
29.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Pacific Biosciences Of California, Inc. (PACB) Q4 2023 Earnings Call Transcript
Positive tone Revio instrument adoption and installed base Onso short-read platform ramp Consumables pull-through and Revio utilization
Revenue
$58.36M*
▲ 113.3% YoY
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
Pacific Biosciences Of California, Inc. (PACB) Q3 2023 Earnings Call Transcript
Revenue
$55.69M
▲ 72.4% YoY
Diluted EPS
$-0.26
Gross margin
32.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pacific Biosciences Of California, Inc. (PACB) Q2 2023 Earnings Call Transcript
Revenue
$47.57M
▲ 34.1% YoY
Diluted EPS
$-0.28
Gross margin
32.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Pacific Biosciences Of California, Inc. (PACB) Q1 2023 Earnings Call Transcript
Revenue
$38.90M
▲ 17.3% YoY
Diluted EPS
$-0.36
Gross margin
25.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Pacific Biosciences Of California, Inc. (PACB) Q4 2022 Earnings Call Transcript
Revenue
$27.35M*
▼ 24.1% YoY
Gross margin
18.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Pacific Biosciences Of California, Inc. (PACB) Q3 2022 Earnings Call Transcript
Revenue
$32.31M
▼ 7.4% YoY
Diluted EPS
$-0.34
▼ 525% YoY
Gross margin
41.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2022 Earnings Call Transcript
Revenue
$35.47M
▲ 15.9% YoY
Diluted EPS
$-0.32
Gross margin
45.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Pacific Biosciences Of California, Inc. (PACB) Q1 2022 Earnings Call Transcript
Revenue
$33.17M
▲ 14.4% YoY
Diluted EPS
$-0.37
Gross margin
42.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Pacific Biosciences Of California, Inc. (PACB) Q4 2021 Earnings Call Transcript
Revenue
$36.02M*
▲ 43.3% YoY
Gross margin
46.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Pacific Biosciences Of California, Inc. (PACB) Q3 2021 Earnings Call Transcript
Revenue
$34.89M
▲ 82.8% YoY
Diluted EPS
$0.08
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2021 Earnings Call Transcript
Revenue
$30.61M
▲ 60.4% YoY
Diluted EPS
$-0.21
Gross margin
44.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Pacific Biosciences Of California, Inc. (PACB) Q1 2021 Earnings Call Transcript
Revenue
$29.00M
▲ 85.9% YoY
Diluted EPS
$-0.45
▼ 4600% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Pacific Biosciences Of California, Inc. (PACB) Q4 2020 Earnings Call Transcript
Revenue
$25.13M*
▼ 10% YoY
Gross margin
45.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Pacific Biosciences Of California, Inc. (PACB) Q3 2020 Earnings Call Transcript
Revenue
$19.08M
▼ 12.9% YoY
Diluted EPS
$-0.14
Gross margin
37.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2020 Earnings Call Transcript
Revenue
$19.08M
▼ 22.5% YoY
Diluted EPS
$-0.15
Gross margin
34.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Pacific Biosciences Of California, Inc. (PACB) Q1 2020 Earnings Call Transcript
Revenue
$15.60M
▼ 5% YoY
Diluted EPS
$0.01
Gross margin
48.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Pacific Biosciences Of California, Inc. (PACB) Q4 2019 Earnings Call
Revenue
$27.93M
▲ 43% YoY
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–31 of 31 earnings calls
Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 5 filings 5 filers Visit website Investor relations